Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.
Human epithelial ovarian cancer is a complex disease, with low 5-yr survival rate largely due to the terminal stage at diagnosis in most patients. MicroRNAs play critical roles during epithelial ovarian cancer progression in vivo and have also been shown to regulate characteristic of ovarian cancer cell line in vitro. Alterative microRNA-224 (microRNA-224) expression affects human epithelial ovarian cancer cell survival, apoptosis, and metastasis. However, people know little about the effects of microRNA-224 on epithelial ovarian cancer cell proliferation. In the current study, we found that the microRNA-224 expression level of human syngeneic epithelial ovarian cancer cells HO8910 (low metastatic ability) was lower than that of HO8910PM (high metastatic ability). Furthermore, microRNA-224 was confirmed to target KLLN in HO8910 and HO8910PM. The known KLLN downstream target cyclin A was regulated by microRNA-224 in HO8910 and HO8910PM. In addition, overexpression of microRNA-224 enhanced the proliferation abilities of HO8910 and knockdown of microRNA-224 suppressed the proliferation abilities of HO8910PM by KLLN-cyclin A pathway. Our results provide new data about microRNAs and their targets involved in proliferation of epithelial ovarian cancer cells by modulating the downstream signaling.
Department of Life Sciences, Bengbu Medical College, Bengbu, People's Republic of China.
Ke
K
Hu
Department of Life Sciences, Bengbu Medical College, Bengbu, People's Republic of China. lmhk@mail.ustc.edu.cn.
Meng
M
Liang
D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019925:Cyclin A / Q000378:metabolism; D015536:Down-Regulation / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D015398:Signal Transduction / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism; D015854:Up-Regulation / Q000235:genetics*
D019925:Cyclin A; C554482:KLLN protein, human; C546140:MIRN224 microRNA, human; D035683:MicroRNAs; D025521:Tumor Suppressor Proteins
Cyclin A; KLLN; MicroRNA-224; Ovarian cancer cells
Diagn Pathol. 2013 Apr 30;8:69
23631806
Biol Reprod. 2009 Jul;81(1):165-76
19357368
PLoS One. 2009;4(4):e5311
19390579
N Engl J Med. 2008 Dec 18;359(25):2720-2
19092157
Cancer Lett. 2014 Feb 28;343(2):249-57
24099915
Lancet Oncol. 2011 Mar;12(3):273-85
21345725
Int J Oncol. 2013 Jun;42(6):1875-82
23588298
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5396-401
18385383
Nat Commun. 2014;5:2977
24394555
Cell. 2005 Jan 14;120(1):15-20
15652477
Oncogene. 2010 Mar 25;29(12 ):1763-72
20023705
Nature. 2004 Sep 16;431(7006):350-5
15372042
Biochem Pharmacol. 2011 Dec 1;82(11):1572-82
21864507
J Natl Compr Canc Netw. 2008 Sep;6(8):795-802
18926090
J Biol Chem. 2008 May 9;283(19):13205-15
18319255
Hum Reprod Update. 2010 Mar-Apr;16(2):142-65
19773286
Mol Cell Endocrinol. 2013 May 6;370(1-2):119-29
23474441
J Exp Clin Cancer Res. 1999 Jun;18(2):233-9
10464713
Biochem Biophys Res Commun. 2012 Aug 24;425(2):127-33
22809510
Int J Cancer. 2014 Aug 1;135(3):541-50
24382668
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
18458333
Eur J Cancer. 2010 Mar;46(4):765-81
20116997
Mol Endocrinol. 2010 Mar;24(3):540-51
20118412
Oncogene. 2013 Sep 5;32(36):4284-93
23045278
Cell Mol Life Sci. 2002 Aug;59(8):1317-26
12363035
Hum Mol Genet. 2013 Jun 1;22(11):2263-72
23418309
J Clin Endocrinol Metab. 2013 Mar;98 (3):E586-94
23386643
Cell. 2004 Jan 23;116(2):281-97
14744438
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
22237781
Cancer Cell Int. 2013 Aug 27;13(1):86
23978303
PLoS One. 2011;6(9):e24541
21912701
Oncol Rep. 2014 Sep;32(3):1003-12
25017423
Science. 2005 Sep 2;309(5740):1519-24
16141061
Eur J Hum Genet. 2015 Nov;23 (11):1538-43
25669429
Ann Surg Oncol. 2009 Aug;16(8):2339-50
19475450
Hum Mol Genet. 2013 Jun 15;22(12 ):2451-61
23446638
Oncol Rep. 2012 Apr;27(4):1238-44
22246341
Front Oncol. 2013 Jun 13;3:153
23785667
Int J Cancer. 2008 Mar 1;122(5):963-8
18098137
Exp Mol Pathol. 2009 Dec;87(3):189-94
19747910
Tumour Biol. 2014 Dec;35(12):12427-34
25201063
J Natl Cancer Inst. 2009 Jun 16;101(12):840-1
19509361
BMB Rep. 2010 Aug;43(8):554-60
20797318
Histopathology. 2010 Nov;57(5):734-43
21083603